Medication Formulation Affects Quality of Life: A Randomized Single-Blind Study of Clobetasol Propionate Foam 0.05% Compared With a Combined Program of Clobetasol Cream 0.05% and Solution 0.05% for the Treatment of Psoriasis

Cutis

Volumn 72, Issue 5, 2003, Pages 407-411

  Bergstrom, Kendra Gail ^a   Arambula, Karina ^a   Kimball, Alexa Boer ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOBETASOL; CLOBETASOL PROPIONATE; DERMATOLOGICAL AGENT; DRUG DERIVATIVE;

ADULT; ARTICLE; BODY SURFACE; CHEMISTRY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; CREAM; DERMATOLOGY; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG SOLUTION; ECONOMICS; FEMALE; FOAM; HOSPITALIZATION; HUMAN; INTRADERMAL DRUG ADMINISTRATION; MALE; PATHOLOGY; PATIENT SATISFACTION; PSORIASIS; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; QUANTITATIVE ANALYSIS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCALP; SCORING SYSTEM; SELF REPORT; SINGLE BLIND PROCEDURE; SKIN; STATISTICAL SIGNIFICANCE; TOPICAL TREATMENT; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; CHEMISTRY, PHARMACEUTICAL; CLOBETASOL; COST-BENEFIT ANALYSIS; DERMATOLOGIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 0346218047     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Ramsay B, O'Reagan M. A survey of the social and psychological effects of psoriasis. Br J Dermatol. 1988;118:195-201.
2. Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001;137:280-284.
3. Melian EB, Spencer CM, Jarvis B. Clobetasol propionate foam, 0.05%. Am J Clin Dermatol. 2001;2:89-92.
4. Fredricksson TPU. Severe psoriasis: oral therapy with a new retinoid. Dermatologica. 1978;157:238-244.
5. Feldman SR, Fleischer AB Jr., Reboussin DM, et al. The self-administered psoriasis area and severity index is valid and reliable. J Invest Dermatol. 1996;106:183-186.
6. Fleischer AB Jr, Feldman SR, Dekle CL. The SAPASI is valid and responsive to psoriasis disease severity changes in a multi-center clinical trial. J Dermatol. 1999;26:210-215.
7. Group TE. EuroQoL - a new facility for the measurement of health-related quality of life: the EuroQuol Group. Health Policy. 1990;16:199-208.
8. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQoL Group. Ann Med. 2001;33:337-343.
9. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dematol. 1994;19:210-216.
10. Krueger GG, Feldman SR, Camisa C, et al. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? what constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol. 2000;43:281-285.
11. Gupta MA, Gupta AK. Age and gender differences in the impact of psoriasis on quality of life. Int J Dermatol. 1995;34:700-703.
12. Lundberg L, Johannesson M, Silverdahl M, et al. Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity. Acta Derm Venereol. 2000;80:430-434.
13. Touw CR, Hakkaart-Van Roijen L, Verboom P, et al. Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin. Br J Dermatol. 2001;144:967-972.
14. Richards HL, Fortune DG, O'Sullivan TM, et al. Patients with psoriasis and their compliance with medication. J Am Acad Dermatol. 1999;41:581-583.